Hisamitsu Pharmaceutical Company, Inc.

Other

Yasuhiro Ikeura

Yasunori Takada

Koji Tanaka

Shinji Yamasoto

Kiyomi Tsuruda

Akira Nakagawa

Kanji Noda

Kazuo Tanaka

Munehiko Hirano

Yasuhisa Kose

Masaru Saita

Yasuaki Taniguchi

Masayoshi Maki

Miyuki Shinmura

Terushi Hashiguchi

Eiji Kyoya

Kazuya Ikawa

Kimihiro Fujii

Tomonori Kurita

A transdermal patch comprising a backingand an adhesive layerlaminated on the backing, wherein the adhesive layercomprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is &#x2153; times by mass to 4 times by mass as that of the rosin-based resin.

Percutaneous absorption type plaster

An anti-inflammatory-containing plaster is provided. The anti-inflammatory-containing plaster may include, e.g., a styrene-isoprene-styrene block copolymer, a high molecular weight polyisobutylene, a low molecular weight polyisobutylene, a tackifier, a plasticizer, a dispersant, and an anti-inflammatory having a carboxyl group or a salt thereof. However, the anti-inflammatory-containing plaster does not contain L-menthol. The anti-inflammatory-containing plaster has medicament release rates of 20-64% by mass and 40-93% by mass at one hour and three hours, respectively.

Method for avoiding crystallization of anti-inflammatory agent in plaster formulation

Percutaneously absorbable preparations (preferably nonaqueous ones, particularly matrix-type patches or ointment), containing salt-form acidic drugs and characterized by being improved in the percutaneous absorbability of the drug by the incorporation of an addition salt of a basic substance therewith and by being lowly irritant to the skin; and a percutaneous absorption accelerator for salt-form acidic drugs, containing an addition salt of a basic substance.

Percutaneously absorbable preparations

This invention provides a patch with less skin stimulation, excellent in long time store stability and heat stability and having favorable tack during use. The patch comprising a styrene-isoprene-styrene block copolymer, polyisobutylene, tackifier, plasticizer and pharmaceutically effective ingredient, in which two or more kinds of polyisobutylene of different average molecular weight are used in combination and the viscosity of the adhesive of the patch is between 1500 and 30,000 poise (at 60&#xb0; C.) and the tack of the patch is from 5 to 200 g/10 mm.

Adhesive preparations

Percutaneous sorbefacients comprising hexylene glycol and 1-menthol, more particularly, percutaneous sorbefacients for female hormones or derivatives thereof; and preparations for percutaneous absorption which comprise a styrene/isoprene/styrene block copolymer and/or polyisobutylene, a softener and a tackifier as the base components, hormones, in particular, follicle hormone and/or luteal hormone as the drug component and hexylene glycol and 1-menthol as a sorbefacient.

Sorbefacients and preparations for percutaneous absorption containing the same

Packaged patch () according to the invention comprises patch () situated in space () inside patch package () composed of laminated packaging material (), and its edges are sealed. Laminated packaging material () comprises hygroscopic material layer () made of LDPE containing 20&#x2013;40 wt % of an inorganic filler, situated between moisture-permeable material layer () made of LDPE and having a moisture permeability of 40&#x2013;120 g/m/day and a screen material layer which blocks penetration of moisture, etc. and is composed of HDPE layer () and aluminum foil (). The saturation hygroscopicity of laminated packaging material () is 2&#x2013;30 g/munder atmosphere conditions with a temperature of 25&#xb0; C. and a relative humidity of 75%. This construction sufficiently reduces the effect of moisture on a drug in patch () and allows patch () to be held in a stable state for prolonged periods, while also improving the economy and handleability of patch package ().

Packaging bag for plaster and packaged plaster

A patch has a backing which has been subjected to an ultraviolet-screening processing, the backing usually being of one layer. The ultraviolet-screening processing usually uses an organic ultraviolet absorbent and/or an inorganic ultraviolet-screening agent. The patch can contain in its base a medicine of poor photo-stability and a non-steroidal anti-inflammatory analgesic.

Ultraviolet-screening patch

A plaster comprising a styrene-isoprene-styrene block copolymer 10-40 wt %, a rosin-based resin 5-30 wt %, a plasticizer 20-70 wt %, polyisobutylene 6-40 wt %, an antioxidant 0.1-5 wt %, and felbinac as a medicinally effective component 1.1-10 wt %, wherein the plaster does not contain crotamiton which is a solubilizer for the felbinac, the felbinac is uniformly dispersed in a semi-solubilized state in the plaster, wherein solubilized felbinac and microcrystalline felbinac coexist in the plaster, and a thickness of the plaster is 50-300 &#x3bc;m.

Plaster containing felbinac

A plaster comprising a styrene-isoprene-styrene block copolymer 10-40 wt %, a rosin-based resin 5-30 wt %, a plasticizer 20-70 wt %, polyisobutylene 6-40 wt %, an antioxidant 0.1-5 wt %, and felbinac as a medicinally effective component 1.1-10 wt %, wherein the plaster does not contain crotamiton which is a solubilizer for the felbinac, the felbinac is uniformly dispersed in a semi-solubilized state in the plaster, wherein solubilized felbinac and microcrystalline felbinac coexist in the plaster, and a thickness of the plaster is 50-300 &mgr;m.

Growing community of inventors

Tosu, Japan

Yasuhiro Ikeura